Results 71 to 80 of about 40,516 (197)

Cost‐Effectiveness of Intensifying Lipid‐Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundA validated prediction model estimates the absolute benefit of intensive versus standard lipid‐lowering therapy (LLT) with statins on next major cardiovascular events for individual patients with coronary artery disease.
Manon C. Stam‐Slob, Yolanda van der Graaf, Jacoba P. Greving, Jannick A.N. Dorresteijn, Frank L.J. Visseren   +4 more
doaj   +1 more source

Efficient use of health care resources: The interaction between improved health and reduced health related income loss [PDF]

Cost effectiveness is a criterion that is often recommended for prioritizing between different types of health care. A modified use of this criterion can be justified as the outcome of a choice that is made “behind a veil of ignorance”.
Hoel, Michael
core  

QALYs gained and costs per 100,000 person-years.

, 2018
QALYs gained and costs per 100,000 person-years.
Laurie Whitsel (4090132), Piotr Bandosz (576531), Simon Capewell (21152), Renata Micha (251302), Yue Huang (285485), Martin O’Flaherty (391936), Dariush Mozaffarian (211862), Chris Kypridemos (719751), Jonathan Pearson-Stuttard (780760), Parke Wilde (4090126), Brendan Collins (762343)   +10 more
core   +1 more source

A test of the predictive validity of non-linear QALY models using time trade-off utilities [PDF]

This paper presents a test of the predictive validity of various classes of QALY models (i.e., linear, power and exponential models). We first estimated TTO utilities for 43 EQ-5D chronic health states and next these states were embedded in health ...
José Luis Pinto, Xabier Badía, José Mª Abellán, Ildefonso Méndez   +3 more
core  

Discounted life years and QALYs for 1 patient.

, 2018
Discounted life years and QALYs for 1 patient.
Franck Maunoury (757097), Vincent Di Martino (561511), Chizoba Nwankwo (4966897), Eric Thervet (497038), Isabelle Durand-Zaleski (132356), Laurie Levy-Bachelot (4966894), Armand Abergel (4966900), Aurore Clément (4966891)   +7 more
core   +1 more source

QALYs: Some Challenges

Value in Health, 2009
In the preceding article, Weinstein et al. [1] explain the QALYconcept, its methods, and their underlying assumptions. Anumber of interesting themes for discussion arise from thisfactual presentation. We restrict ourselves to addressing fourissues that we deem particularly challenging.As a general background for our selection of issues, we reit-erate a
Nord, Erik, Daniels, Norman, Kamlet, Mark   +2 more
openaire   +2 more sources

Lifetime costs and QALYs of screening versus no-screening.

, 2018
Lifetime costs and QALYs of screening versus no-screening.
Wantanee Kulpeng (744964), Yot Teerawattananon (180232), Chutima Kumdee (6029396)   +2 more
core   +1 more source

Cost-utility and budget impact analysis of laparoscopic bariatric surgery for obesity with Type II Diabetes Mellitus in Thailand.

PLoS ONE
Bariatric surgery is another treatment options for patients with obesity, who cannot achieve weight controlled by conservative non-surgical therapy. Although bariatric surgery provides clinical benefits for these patients, it is costly.
Prapaporn Noparatayaporn, Montarat Thavorncharoensap, Usa Chaikledkaew, Panu Looareesuwan, Prapimporn Chattranukulchai Shantavasinkul, Preeda Sumritpradit, Ammarin Thakkinstian   +6 more
doaj   +1 more source

QALYs and mental health care

, 1997
Quality-adjusted life year measures (QALYS) have been fervently debated by researchers and decision makers concerned with resource allocation in the health care sector. They have been heralded as important aids to planning and priority setting, but also
Chisholm, D., Knapp, M., Healey, Andrew T., Chisholm, Daniel, Healey, A., Knapp, Martin R J.   +5 more
core   +1 more source

International cost-effectiveness analysis in osimertinib after chemoradiotherapy in stage III EGFR-mutated non-small cell lung cancer

Frontiers in Public Health
BackgroundThe international Phase 3 LAURA trial (NCT03521154) demonstrated that the use of osimertinib following chemoradiotherapy markedly improved survival outcomes in unresectable stage III NSCLC with epidermal growth factor receptor (EGFR) mutations.
Diya Tang, Xi Zou, Chaochao Wei, Chaochao Wei, Chaochao Wei, Chaochao Wei, Xiaoyu Zhang   +6 more
doaj   +1 more source